1. The above audited financial results for the quarter and year ended on December 31, 2008 were approved at the meeting of the Board of Directors held on March 31, 2009, after being approved and recommended by the Audit Committee.

2. The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standards (AS-17) On "Segment Reporting" issued by ICAI, is not applicable.

3. The EPS has been computed in accordance with the accounting standard (AS-21) issued by the ICAI.

4. Figures of the previous year wherever necessary have been regrouped and reclassified to conform to those of the current year.

5. The cost of Packing materials has been Included in other expenditure, whereas Directors´ remuneration has been included In the employees cost.

6. The consolidated financial results for the accounting year ended on December 31, 2008 include the results of its wholly owned subsidiaries namely M/s. Plethico Global Holdings B.V., Netherlands and Plethico International Ltd, UAE. The figures of Plethico Global Holding B.V. of previous quarts have been regrouped and/ or rearranged wherever necessary due to Indian GAAP audit conducted.

7. Extra-ordinary items is related to unrealized exchange loss of Rs 6825 Lacs arising on account of restatement of outstanding Foreign Currency Convertible Bonds (FCCB) at the rate prevailing at the year end. This loss is a non-cash charge.

8. Premium payable on redemption of FCCB for the period up to December 31, 2008 amounting to Rs 3433.47 lacs has been provided out of Share Premium Account.

Shashikant Patel
Chairman cum Managing Director